Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive Tepotinib.

- CrCl <30 mL/min
- Prior treatment with another MET inhibitor
- Moderate or Severe Hepatic Insufficiency: AST/ALT > 3 × ULN or total bilirubin > 1.5 × ULN. For patients with liver metastases: AST/ALT > 5 × ULN or total bilirubin > 1.5 × ULN.
- Inadequate hematologic function with one of the following: Hgb <8.5 g/dL or Neutrophils <1.5 x 10^9/L or Plt <100 x 10^9/L
- Presence of ALK mutation or sensitive EGFR mutation (exon 19 del or exon 21 alteration)
- NYHA heart failure Class III or IV
- Untreated brain metastases
- Pregnancy (i.e. known pregnancy or positive pregnancy test)
- Breastfeeding

Inclusion Criteria

The answers to ALL of the following must be fulfilled in order to meet criteria.

- Care is provided by a VA/VA Community Care oncology provider
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Goals of care and role of Palliative Care consult have been discussed and documented
- Patients of child-bearing potential and patients with partners of child-bearing potential: counseling provided on contraception and risks vs. benefits of treatment. Use effective contraception during therapy and for one week after the last dose.

Additional Inclusion Criteria

The answer to the following must be fulfilled in order to meet criteria:

- Patients with metastatic non-small cell lung cancer with a MET exon 14 skipping mutation

Prepared: November 2021. Contact: Mark C. Geraci, Pharm.D., BCOP, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services 10P4P

Updated version may be found at PBM INTERnet or PBM INTRAnet